Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
At least one person has died in the crash after the plane came down in the city of Riverside shortly after take off.
The animal is believed to have been attacked with metal bars, knives and rocks and later died of his injuries.
More than 20,000 allegations of abuse by care home workers have been made in the last three years, figures show.